Report Details
Where is the pharma market in China heading? Visiongain's report shows you its potential revenues to 2022, discussing opportunities and developments.
Discover sales predictions at overall market and submarket levels. Our study gives you business research, analysis and opinion for drug sales in China. Find data and trends there.
See how Chinese submarkets can perform to 2022 - patented brands, generics, OTC products, traditional medicines, anti-infectives, vaccines, cardiovascular/cerebrovascular, alimentary/metabolic, cancer and CNS drugs. You view potential revenues, with discussions.
How will governmental reform of the healthcare system affect the pharmaceutical industry? Will patented branded products achieve greater market penetration this decade?
Opportunities multiply. The government's Healthy China 2020 plan will mean up to $1.4 trillion invested. See the effects of rising purchase power and widening medical coverage, discovering prospects from 2012. You find information, calculations and views in this report.
Medical R&D in China is gaining prominence. Assess the trends behind its emergence as a biopharmaceutical hub, reviewing progress in outsourced research and manufacturing.
The report discusses many domestic companies, such as China National Biotec Group, Sinopharm, WuXi AppTec, Sinovac Biotech and Beijing Pharmaceutical Group. Biopharma industry is flourishing.
View activities of multinationals too, including Pfizer, Sanofi, Bayer, AstraZeneca, Roche, Novartis, GSK, Merck, Eli Lilly and Novo Nordisk. This is the country to watch for developments in healthcare. Our investigation shows you why.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In the report, you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), opinions and news. You receive 72 tables and charts and two research interviews.
Advantages of Chinese Pharmaceutical Market 2012-2022 for your work
In particular, this study gives you the following knowledge and benefits:
• Find revenue predictions to 2022 for the overall Chinese pharma market and submarkets, seeing revenue growth
• Read sections on 40 prominent companies there, viewing developments in biotechnology and other aspects of medicine
• Investigate competition and opportunities influencing sales results
• Find out what will stimulate and restrain the market, affecting its growth
• See emerging trends in biopharma R&D, contract research and manufacturing
• Appraise therapeutic and commercial needs, as well as healthcare policy
• View opinions from our survey of authorities on the sector.
There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse activities and events, helping you to stay ahead.
Gain pharma business research, data and analysis for the leading emerging country
Our study is for everybody needing industry and market analyses for the drug market in China. Find data, trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Drug And Medication Industry in China
Table of Contents
1. Executive Summary
1.1 China: Pharmaceutical Market Review
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. Chinese Pharmaceutical Market: An Overview
2.1 China: National Overview
2.1.1 China's Rise as an Economic Superpower
2.2 From Maoism to Market: Chinese Healthcare Since World War II
2.2.1 Socialised Healthcare
2.2.2 Developments Since 1992
2.2.3 Investment, But Healthcare Disparities Remain
2.3 The Rise of the Chinese Pharmaceutical Market
2.3.1 Picking up the Tab
2.4 Healthy China 2020: 'Unprecedented in Human History'
2.4.1 Achievements and Potential of the Healthy China 2020 Initiative
2.5 Demography and Disease Burden in China
2.5.1 The Ageing Population
2.5.2 Obesity in China
2.5.3 Stroke, Heart Disease and Diabetes
2.5.4 Cancer and Respiratory Diseases
2.5.5 Communicable Diseases
2.6 Other Aspects of the Chinese Market
3. The Chinese Pharmaceutical Market, 2012-2022
3.1 Chinese Pharmaceutical Market: Forecast, 2012-2022
3.2 The Product Mix in China, 2010
3.3 The Product Mix in China, 2012-2022
3.4 Prescribed Patented Brands: Forecast, 2012-2022
3.4.1 Drivers and Restraints for Patented Prescription Drugs
3.5 Prescribed Generics: Forecast, 2012-2022
3.5.1 Drivers and Restraints for Prescribed Generics
3.6 OTC Products: Forecast, 2012-2022
3.6.1 Drivers and Restraints for OTC Products
3.7 TCM Products: Forecast, 2012-2022
3.7.1 Drivers and Restraints for TCM Products
4. Leading Therapeutic Areas in the Chinese Market, 2012-2022
4.1 Anti-Infectives Market, 2012-2022
4.1.1 Antibiotics: China's Drugs of Choice
4.1.2 Antivirals: a Growth Area
4.2 Cancer Treatments Market, 2012-2022
4.2.1 Small Molecules Dominate the Chinese Cancer Drug Market
4.3 Cardiovascular/Cerebrovascular Market, 2012-2022
4.3.1 Anti-Aggregants, Statins and Vasotherapeutics
4.4 Alimentary and Metabolic Diseases Market, 2012-2022
4.4.1 Antiulcerants and Diabetes Treatments
4.5 Central Nervous System Diseases Market, 2012-2022
4.5.1 Pain Relief
4.5.2 Anti-Depressants
4.5.3 Neurodegenerative Diseases
4.6 Vaccines Market, 2012-2022
4.6.1 Opportunities and Challenges in Vaccines
4.7 Other Therapeutic Classes Market, 2012-2022
5. China as a Pharmaceutical Hub, 2012-2022
5.1 China as a Manufacturing Hub
5.1.1 China's API Export Market
5.1.2 Contract Manufacturing Organisations: Beyond APIs
5.2 China as a Research Hub
5.2.1 Clinical Trials in China
5.2.2 The Rise of China's Contract Research Organisations
5.3 China as a Biotechnology Hub
5.3.1 Leading the Way in Biosimilars
5.3.2 Biomarkers and Genomic Sequencing
5.3.3 Stem Cells in China
5.3.4 Other Regenerative Medicine in China
5.4 China as a Pharmaceutical Hub: Conclusions
6. Key Domestic Players in the Chinese Market, 2012
6.1 Fragmentation and Consolidation Among Chinese Companies
6.2 Summary of Leading Domestic Companies
6.3 China National Pharmaceutical Corporation (Sinopharm)
6.4 China National Biotec Group (CNBG)
6.5 WuXi AppTec
6.6 CSPC Pharmaceutical Group
6.7 Beijing Pharmaceutical Group
6.8 Shanghai Pharmaceutical Group (SPGC)
6.9 Yangtze River Pharmaceutical Group
6.10 Tianjin Pharmaceuticals Group Corporation (TJPC)
6.11 Taiji Group
6.12 C&O Pharmaceutical Technology Holdings
6.13 Harbin Pharmaceutical Group Holding Company
6.14 Guangzhou Pharmaceutical Holdings
6.15 Sinovac Biotech (Beijing Kexing Bioproducts)
6.16 Tongrengtang Pharmaceutical
6.17 Buchang Pharmaceutical
6.18 Northeast Pharmaceutical Group (NEPG)
6.19 China Nepstar Chain Drugstore
6.20 Zhejiang Huahai Pharmaceuticals
6.21 Hangzhou Zhongmei Huadong Pharmaceutical
6.22 Hualan Biological Engineering
6.23 China Sky One Medical
6.24 Zensun (Shanghai) Sci & Tech
6.25 Ascletis
6.26 Shangdong Dong-E-E-Jiao
6.27 Mindray Medical International and China Medical Technologies
7. Key Multinational Players in the Chinese Market, 2012
7.1 Bayer Schering
7.2 AstraZeneca
7.3 Pfizer
7.4 Sanofi
7.5 Roche
7.6 Novartis
7.7 GlaxoSmithKline
7.8 Merck & Co.
7.9 Novo Nordisk
7.10 Eli Lilly
7.11 Abbott Laboratories
7.12 Johnson & Johnson
7.13 Bristol-Myers Squibb
7.14 Teva Pharmaceutical Industries
7.15 Takeda
8. The Chinese Pharma Market: Qualitative Analysis
8.1 Strengths: Government Investment Will Further Expand this Dynamic Market
8.2 Weaknesses: IP and Regulatory Challenges Remain
8.3 Opportunities: The Scramble for China
8.4 Threats: A House Built on Sand?
9. Research Interviews
9.1 Interview with Dr Derek Lowe, Drug Discovery Expert
9.1.1 On the Rising Cost of Outsourcing Research to China
9.1.2 On Building Relationships in the Chinese Market
9.1.3 On Prospects for Western Brands in the Chinese Market
9.1.4 On IP Protection and Safety Concerns in China
9.1.5 On the Role of the Chinese State in the Pharmaceutical Market
9.1.6 On Biotechnology and the Chinese Research Culture
9.1.7 On Chinese Biosimilar Manufacturing
9.2 Interview with Dr Jean-Pierre Wery, President, Crown Bioscience, China
9.2.1 Contract Research Services Offered by Crown Bioscience
9.2.2 On Technological Platforms and Animal Models Relevant to Biomarkers
9.2.3 On the Range of Therapeutic Areas Covered by Crown Bioscience
9.2.4 On Translational Medicine and Patient Stratification
9.2.5 On the Future for Crown Bioscience and Other CROs
10. Conclusions
10.1 The Chinese Pharma Market Will Continue to Grow Rapidly
10.2 Treatments for Chronic Diseases Will Challenge the Anti-Infectives Sector
10.3 China Will Continue to Grow as a Focus for the Multinational Industry
10.4 China is Set to be the Most Important Pharmaceutical Market, Despite Weaknesses
List of Tables
Table 2.1 Causes of Mortality in China, 2002
Table 3.1 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2010-2015
Table 3.2 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2016-2022
Table 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010
Table 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015
Table 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022
Table 3.8 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.9 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 3.10 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.11 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 3.12 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.13 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 3.14 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.15 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010
Table 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015
Table 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022
Table 4.6 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.7 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.8 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.9 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.12 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.13 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.14 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.15 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.16 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.17 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.18 Other Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.19 0ther Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 8.1 Strengths and Weaknesses in the Chinese Pharma Market, 2012-2022
Table 8.2 Opportunities and Threats in the Chinese Pharma Market, 2012-2022
List of Figures
Figure 2.1 Causes of Mortality in China, 2002
Figure 3.1 Chinese Pharmaceutical Market: Revenues ($bn), 2010-2015
Figure 3.2 Chinese Pharmaceutical Market: Revenues ($bn), 2016-2022
Figure 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010
Figure 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2010-2015
Figure 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015
Figure 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2016-2022
Figure 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022
Figure 3.8 Prescribed Patented Brands Market: Revenues ($bn), 2010-2015
Figure 3.9 Prescribed Patented Brands Market: Revenues ($bn), 2016-2022
Figure 3.10 Prescribed Generics Market: Revenues ($bn), 2010-2015
Figure 3.11 Prescribed Generics Market: Revenues ($bn), 2016-2022
Figure 3.12 OTC Products Market: Revenues ($bn), 2010-2015
Figure 3.13 OTC Products Market: Revenues ($bn), 2016-2022
Figure 3.14 TCM Products Market: Revenues ($bn), 2010-2015
Figure 3.15 TCM Products Market: Revenues ($bn), 2016-2022
Figure 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010
Figure 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2010-2015
Figure 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015
Figure 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2016-2022
Figure 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022
Figure 4.6 Anti-Infectives Market: Revenues ($bn), 2010-2015
Figure 4.7 Anti-Infectives Market: Revenues ($bn), 2016-2022
Figure 4.8 Oncology Market: Revenues ($bn), 2010-2015
Figure 4.9 Oncology Market: Revenues ($bn), 2016-2022
Figure 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2010-2015
Figure 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2016-2022
Figure 4.12 Alimentary/Metabolic Market: Revenues ($bn), 2010-2015
Figure 4.13 Alimentary/Metabolic Market: Revenues ($bn), 2016-2022
Figure 4.14 CNS Diseases Market: Revenues ($bn), 2010-2015
Figure 4.15 CNS Diseases Market: Revenues ($bn), 2016-2022
Figure 4.16 Vaccines Market: Revenues ($bn), 2010-2015
Figure 4.17 Vaccines Market: Revenues ($bn), 2016-2022
Figure 4.18 Other Therapeutic Classes Market: Revenues ($bn), 2010-2015
Figure 4.19 0ther Therapeutic Classes Market: Revenues ($bn), 2016-2022
Companies Listed
Abbott Laboratories
Acambis
Agilent Technologies
American California Pharmaceutical Group
Anhui BBCA Biochemical
AppTech Laboratory Services
Ascletis
Asian Cancer Research Group
AstraZeneca
Aurobindo Pharma
AXM Pharma
Bayer Schering Pharma
Beijing Bio-Ekon Biotechnology
Beijing Double-Crane Pharmaceutical Business
Beijing GP Medical Technologies
Beijing Haiyan Pharmaceutical Company
Beijing Pharmaceutical Group
Beijing Shuanglu
Beijing Tiantan Biological Products
Beijing Union Medical College Hospital
Beijing University
Beijing Wandong Medical Equipment
Beijing Yuande Bio-Medical Engineering
BGI (formerly Beijing Genomics Institute)
Biocon
BioDura
BioMarin Pharmaceutical
Bioton
BMP Sandstone
Bristol-Myers Squibb
Broad Institute
Buchang Pharmaceutical
C&O Pharmaceutical Technology Holdings
Cai Zhi Lin Pharmacies
Cancer Therapeutics
Charles River Laboratories
China Aoxing
China Chain Stores and Franchise Association (CCSFA)
China Medical Technologies
China National Biotec Group
China National Pharmaceutical Corporation (Sinopharm)
China Nepstar Chain Drugstore
China Pharmaceutical Group (China Pharma)
China Sky One Medical
ChinaBio Therapeutics
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chinese Diabetes Society
Chongqing Taiji Industry Group
Chongqing Tongjunge
Cipla
Cord Blood America
Covance
Crown Bioscience
Crucell Biotechnology
CSPC Pharmaceutical Group
CSPC Zhongrun
Cumencor Pharmaceuticals
Denosim
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Eisai
Eli Lilly
European Medicines Agency (EMEA/EMA)
Excel PharmaStudies
FeRx
Food and Drug Administration (FDA, US)
Frontage Laboratories
GenScript
Genzyme Corporation
GlaxoSmithKline
Goldman Sachs Group
Greater China Corporation
Guangdong Province People's Hospital
Guangzhou Medical University
Guangzhou Pharmaceutical Company
Guangzhou Pharmaceutical Holdings
Habin Tian Di Ren Medical Science and Technology
Hangzhou Sanofi-Synthelabo Minsheng
Hangzhou Zhongmei Huadong Pharmaceutical
Harbin Pharmaceutical Group
HD Biosciences
Hebei Pharmaceutical Group
Huadong Medicine Company
Hualan Biological Engineering
Hutchison MediPharma
Institute for BioMedical Research (Shanghai)
International Diabetes Foundation
Introgen Therapeutics
Ivax Corporation
Jian Min Pharmacies
Jiangsu Haici Biological Pharmacy Company
Jiangsu New Medicine Research Institution
Jiangsu Walvax Biotech
Johnson & Johnson
Knoll
LEAD Pharmaceuticals
LG Life Sciences
Lundbeck
Merck & Co.
MicuRx Pharmaceuticals
Mindray Medical International
Ministry of Commerce (China)
Ministry of Science and Technology (China)
Minsheng Pharmaceutical
Mirahi Biotech
Nanjing Hailing National Engineering Research Center
Nanjing Hailing Pharmaceutical Company
National Center for Drug Screening (China)
New England Journal of Medicine
Northeast General Pharmaceutical
Northeast Pharmaceutical Group (NEPG)
NorthEast Pharmacy Chain
NovaMed Pharmaceuticals
Novartis
Novartis China
Novo Nordisk
Nycomed Amersham
Organization for Economic Cooperation and Development (OECD)
Patheon
Pfizer
Piramal Healthcare Solutions
PlaNrt Finance
Provincial Institute for the Control of Pharmaceutical and Biologic Products (China)
Qilu Pharmaceutical
QRxPharma
Roche
Sandoz (part of Novartis)
Sanjing Pharmaceutical
Sanofi
Shandong Dong-E E-Jiao
Shanghai Zhong Hua Pharmaceutical Factory (Jiang Qiao Branch)
Shanghai ChemExplorer
Shanghai Haini Pharmaceutical Company
Shanghai Huai Hai Pharmaceutical Factory
Shanghai Institute for Biological Sciences
Shanghai Institute of Materia Medica
Shanghai Jiao Tong University
Shanghai No. 6 Pharmaceutical Factory
Shanghai Pharmaceutical Group (SPGC)
Shanghai Qisheng
Shanghai Schering-Plough
Shanghai Sunve Pharmaceutical
Shanghai Xin Hua Lian Pharmaceutical
Shenzhen Neptunus Interlong Bio-Technique
Shenzhen SiBiono GeneTech
Shijiazhuang Pharmaceutical Group
Shire Pharmaceuticals
SiBiono
Sichuan Hairong Pharmaceutical Company
Sicor Pharmaceuticals
SiniWest Holdings
Sino-American Kunming Baker Norton Pharmaceutical
Sinopharm
Sinovac Biotech (Beijing Kexing Bioproducts)
Solvay Pharmaceuticals
Southwest Pharmaceutical
State Food and Drug Administration (SFDA)
State Key Lab of Respiratory Disease
Sundia Meditech
Sunway Biotech
Suzhou Novartis Pharma Technology
Taiji Group
Takeda Pharmaceutical
Tangshan Yian Bioengineering
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Tianjin International Joint Academy of Biotechnology and Medicine
Tianjin Jin Yao Group
Tianjin Medical University Cancer Hospital
Tianjin Pharmaceutical Factory
Tianjin Pharmaceuticals Group Corporation
Tianjin Takeda Pharmaceuticals
Tonghua Dongbao
Tongrentang Pharmaceutical
Tsinghua University
UNICEF
United Pharmatech
Vertex Pharmaceuticals
Weisheng Pharmaceutical
Working Group on Obesity in China
World Health Organization (WHO)
World Trade Organization (WTO)
Wuhan National Bioindustry Base Construction
WuXi AppTec
WuXi PharmaTech
Wyeth (now part of Pfizer)
Xian-Janssen Pharmaceuticals
Yangtze River Pharmaceutical Group
Yunnan Walvax BiotechJiangsu Pharmaceutical Company
Zensun (Shanghai) Sci & Tech
Zhejiang Huahai Pharmaceuticals
Zhejiang Medicine
Zhejiang Tianyuan
Zhongnuo
Zydus Cadila
